[fullwidth background_color=”” background_image=”” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_repeat=”no-repeat” background_position=”left top” video_url=”” video_aspect_ratio=”16:9″ video_webm=”” video_mp4=”” video_ogv=”” video_preview_image=”” overlay_color=”” overlay_opacity=”0.5″ video_mute=”yes” video_loop=”yes” fade=”no” border_size=”0px” border_color=”” border_style=”” padding_top=”20″ padding_bottom=”20″ padding_left=”” padding_right=”” hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”no” menu_anchor=”” class=”” id=””][title size=”1″ content_align=”center” style_type=”default” sep_color=”” margin_top=”” margin_bottom=”” class=”” id=””]Lamellar Ichthyosis Clinical Trials[/title][fusion_text]Mayne protocol 18-ICH-001: A Phase 2 Randomized, Multicenter, Doubleblind, Vehicle Controlled, 12 Week, Safety, Efficacy & Systemic Exposure Study Followed by a 12 Week Open-label Extension of CD5789 in Adults and Adolescents With Autosomal Recessive Ichthyosis With Lamellar Scale – CURRENTLY ENROLLING
- A phase II study for patients with a genetic condition called lamellar ichthyosis.
- We are looking for patients with ichthyosis with lamellar scale to participate in a trial investigating trifarotene cream (topical retinoid). 2/3 chance of receiving the medication for the first 3 months, after that all patients will receive open-label trifarotene. Enrolling now!
[/fusion_text][/fullwidth]